Literature DB >> 19043439

End of the line for cannabinoid receptor 1 as an anti-obesity target?

Dan Jones.   

Abstract

A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19043439     DOI： 10.1038/nrd2775

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  32 in total

1.  Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.

Authors:  Christopher J Lynch; Qing Zhou; Show-Ling Shyng; David J Heal; Sharon C Cheetham; Keith Dickinson; Peter Gregory; Michael Firnges; Ulrich Nordheim; Stephanie Goshorn; Dania Reiche; Lechoslaw Turski; Jochen Antel
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

Review 2.  Inflammatory lipid mediators in adipocyte function and obesity.

Authors:  Abishek Iyer; David P Fairlie; Johannes B Prins; Bruce D Hammock; Lindsay Brown
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

3.  End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.

Authors:  Maurizio Bifulco; Simona Pisanti
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

4.  Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats.

Authors:  Jonathan A Farrimond; Andrew J Hill; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2010-03-27       Impact factor: 4.530

5.  Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

Authors:  Jason D Robinson; Paul M Cinciripini; Maher Karam-Hage; Henri-Jean Aubin; Lowell C Dale; Raymond Niaura; Robert M Anthenelli
Journal:  Addict Biol       Date:  2017-04-21       Impact factor: 4.280

Review 6.  Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Authors:  Kathryn A Seely; Paul L Prather; Laura P James; Jeffery H Moran
Journal:  Mol Interv       Date:  2011-02

Review 7.  Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Authors:  Thuy Nguyen; Jun-Xu Li; Brian F Thomas; Jenny L Wiley; Terry P Kenakin; Yanan Zhang
Journal:  Med Res Rev       Date:  2016-11-23       Impact factor: 12.944

Review 8.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

9.  Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand.

Authors:  Garth E Terry; Jeih-San Liow; Sami S Zoghbi; Jussi Hirvonen; Amanda G Farris; Alicja Lerner; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Jinsoo S Hong; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Neuroimage       Date:  2009-06-30       Impact factor: 6.556

Review 10.  The endocannabinoid system: potential for reducing cardiometabolic risk.

Authors:  Henry N Ginsberg; Stephen C Woods
Journal:  Obesity (Silver Spring)       Date:  2009-04-16       Impact factor: 5.002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.